Skip To Main Content
Andrew S. Chi on Muck Rack

Andrew S. Chi

As seen in: The Oncologist, The New England Journal of Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Andrew S. Chi’s profile

Articles by Andrew S. Chi

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

|
By Andrew S. Chi, Daniel Cahill, David A Reardon, Patrick Y Wen
| ascopubs.org
Article Tools ORIGINAL REPORTS Andrew S. Chi, MD, PhD1; Daniel P. Cahill, MD, PhD1; David A. Reardon, MD2; Patrick Y. Wen, MD2; Tom Mikkelsen, MD3,4; David M. Peereboom, MD5; Eric T. Wong, MD6; Elizabeth R. Gerstner, MD1; Jorg Dietrich, MD, PhD, MMSc, MBA1; Scott R. Plotkin, MD, PhD1; Andrew D. Norden, MD2; Eudocia Q. Lee, MD, MPH2; Lakshmi Nayak, MD2; Shota Tanaka, MD, PhD1; Hiroaki Wakimoto, MD, PhD1; Nina Lelic, BS1; Mara V. Koerner, MD1; Lindsay K. Klofas, BA1; Mia S. Bertalan, BA1; Isabel C.
Open in Who Shared Issue with article?

Case 38-2016 - A 52-Year-Old Woman with Recurrent Oligodendroglioma

|
By Andrew S. Chi, Daniel Cahill, David Louis, Mykol Larvie
| The New England Journal of Medicine Verified
This article is available to subscribers.Sign in now if you're a subscriber. A 52-year-old woman who had had low-grade oligodendroglioma 12 years earlier was seen for routine follow-up. Imaging studies revealed progression of the lesion. She was referred for neurosurgical evaluation. This case was presented at Neurology Grand Rounds. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?

In Reply

|
By Amir T. Fathi, Andrew S. Chi
| The Oncologist Verified
We appreciate the comments provided by Lombardi et al. [1] regarding our article [2] and acknowledge that they raise several important points. It is true that our patient population was heterogeneous, with glioma diagnoses at various grades and stages of treatment, and we noted these limitations in our report. In addition, our study had relatively few IDH wild-type patients and included heterogeneous IDH mutations, as Lombardi et al. point out.
Open in Who Shared Issue with article?
Show More